Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples